Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.41 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 6/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14062029 | 0.87 | CYP24A1 (0.49) | DRD2CYP24A1CYP27A1CYP26A1ACHE | |
| SCHEMBL17211830 | 0.83 | PARP10 (0.39) | CYP24A1CYP27A1CYP26A1ACHE | |
| SCHEMBL14137074 | 0.82 | CYP26A1 (0.46) | CYP24A1CYP26A1CYP19A1 | |
| SCHEMBL14061800 | 0.81 | CYP24A1 (0.48) | DRD2DRD3HTR1DCYP24A1CYP27A1 | |
| SCHEMBL14062048 | 0.80 | CYP24A1 (0.47) | DRD2DRD3HTR1DCYP24A1CYP27A1 | |
| SCHEMBL2472482 | 0.79 | CYP24A1 (0.50) | DRD2CYP24A1CYP27A1CYP26A1ACHE | |
| SCHEMBL14062034 | 0.78 | CYP26A1 (0.39) | CYP24A1CYP26A1 | |
| SCHEMBL1500201 | 0.76 | DRD2 (0.47) | DRD2DRD3HTR1DCYP24A1CYP27A1 | |
| SCHEMBL14137078 | 0.76 | ITGB3 (0.56) | CYP24A1CYP27A1CYP26A1CYP19A1 | |
| SCHEMBL14062072 | 0.75 | ALDH1A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2723332-B1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| EP-2723332-B1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| US-9242929-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242929-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) | 2015-10-29 | — | — | US | disclosed |
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) | 2015-10-29 | — | — | US | disclosed |
| WO-2012162127-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | DGAT1, DGAT2, LCAT | DRD2 2863/4885DRD3 2151/4885HTR1D 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.